atenolol has been researched along with Left Ventricular Hypertrophy in 203 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 9.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| "Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations." | 9.19 | Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. ( Abraham, TN; Agarwal, R; Pappas, MK; Sinha, AD; Tegegne, GG, 2014) |
| " We examined whether PP predicted new-onset AF in comparison with other blood pressure components in the Losartan Intervention For Endpoint reduction in hypertension study, a double-blind, randomized (losartan versus atenolol), parallel-group study, including 9193 patients with hypertension and electrocardiographic left ventricular hypertrophy." | 9.16 | Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| "Eight thousand one hundred ninety-four LIFE patients with hypertension and left ventricular hypertrophy with available baseline hemoglobin measurements were randomized to losartan- or atenolol-based treatment and followed for 4." | 9.14 | Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Narayan, P; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wedel, H, 2009) |
| "ECG strain was evaluated at baseline and after 1 year of therapy in 7409 hypertensive patients in the LIFE study (Losartan Intervention For End-point reduction in hypertension) treated in a blinded manner with atenolol- or losartan-based regimens." | 9.14 | Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). ( Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2009) |
| "The MPI was measured at baseline and after 48 weeks of antihypertensive treatment in 93 participants of the SILVHIA trial, where individuals with primary hypertension and left ventricular hypertrophy were randomized to double blind treatment with either irbesartan or atenolol." | 9.14 | The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SI ( Arnlöv, J; Kahan, T; Liljedahl, S; Lind, L, 2009) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study compared effects of losartan-based versus atenolol-based therapy on cardiovascular events in 9193 patients with hypertension and LVH." | 9.14 | Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2009) |
| "It is unclear whether serum uric acid (SUA) is associated with development of new-onset diabetes (NOD) in patients with hypertension and left ventricular hypertrophy (LVH)." | 9.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| "8 years of randomized losartan- or atenolol-based treatment in the Losartan Intervention for Endpoint Reduction in Hypertension Echocardiography substudy." | 9.13 | Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Boman, K; Cramariuc, D; de Simone, G; Devereux, RB; Gerdts, E; Okin, PM; Wachtell, K, 2008) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 9.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 9.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "Hypertensive patients with electrocardiographic-left ventricular hypertrophy were randomized to losartan-based or atenolol-based treatment and followed for 4." | 9.13 | Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Jern, S; Kjeldsen, SE; Li, Z; Nieminen, MS; Okin, PM; Wachtell, K, 2008) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 9.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 9.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 9.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "LIFE was a randomized, double-blind trial comparing losartan-based and atenolol-based treatment regimens on the primary composite endpoint of death, myocardial infarction (MI), or stroke in 9193 patients aged 55-80 years with hypertension and left ventricular hypertrophy." | 9.12 | Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Hille, DA; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2007) |
| "The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, doubleblind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease (CVD)-related morbidity and mortality in 9193 patients with hypertension and left-ventricular hypertrophy (LVH)." | 9.12 | An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007) |
| "Patients with mild to moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta(1)-adrenergic receptor blocker atenolol (n = 49) as monotherapy." | 9.11 | Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. ( Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Syvänen, AC, 2004) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study was designed to compare losartan- vs atenolol-based antihypertensive treatment on cardiovascular morbidity and mortality in a population of 9193 hypertensive patients with left ventricular hypertrophy (LVH)." | 9.11 | Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, GW; Dahlöf, B; Devereux, RB; Diener, HC; Edelman, JM; Krobot, K, 2004) |
| "We determined the association between the TGF-beta1 genotype and regression of LV mass in 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, randomized in a double-blind study to receive treatment for 48 weeks with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor blocker atenolol." | 9.11 | Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Billberger, K; Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaelsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2004) |
| "To assess the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment, we related age to clinical and echocardiographic findings before and after 4 years of antihypertensive treatment in a subset of 560 hypertensive patients without known concurrent disease in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which randomized patients to blinded losartan- or atenolol-based treatment." | 9.11 | Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). ( Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Roman, MJ; Smith, G; Wachtell, K, 2004) |
| "We determined the preproendothelin-1 genotype using minisequencing in 102 patients with essential hypertension and LV hypertrophy verified by echocardiography, randomized in a double-blind fashion to treatment with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol." | 9.11 | Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2004) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 9.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left ventricular (LV) mass more than atenolol." | 9.11 | Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. ( Boman, K; Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 9.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up." | 9.11 | Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy." | 9.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 9.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH)." | 9.11 | The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "In 183 patients with hypertension and electrocardiographic left ventricular (LV) hypertrophy, enrolled in the LIFE Study, we measured BP and serum Nt-proANP and Nt-proBNP by immunoassay after 2 weeks of placebo treatment and after 1, 2, 4, 6, 12, 24, 36 and 48 months of randomized treatment with losartan- or atenolol-based antihypertensive regimens." | 9.11 | Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. ( Bang, LE; Devereux, RB; Fossum, E; Hall, C; Hildebrandt, PR; Ibsen, H; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K, 2005) |
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 9.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "We conducted a subgroup analysis in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study to determine whether aspirin interacted with the properties of losartan, an angiotensin-II receptor antagonist." | 9.11 | The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fossum, E; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Moan, A; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "To compare the effects of the angiotensin II antagonist, losartan, with those of atenolol on left ventricular hypertrophy (LVH), blood pressure and neurohormone concentrations in hypertensive patients with LVH." | 9.10 | Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. ( Aurup, P; Barrios, V; Dahlof, B; Diez, J; Johansson, M; Nicholls, MG; Smith, RD; Yu, CM; Zanchetti, A, 2002) |
| "In the LIFE study, with a double-masked, randomized, parallel-group design, 9193 patients (46% men) with hypertension (mean age 67 years, average pressure 174/98 mmHg after placebo run-in) and electrocardiogram-documented left ventricular hypertrophy were randomly assigned to once-daily losartan- or atenolol-based antihypertensive treatment and followed for at least 4 years (mean 4." | 9.10 | Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. ( Aurup, P; Beevers, G; Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Snapinn, S; Wachtell, K; Wedel, H, 2002) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 9.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "One hundred and two patients with essential hypertension and left ventricular hypertrophy were allocated randomly to groups to receive double-blind treatment with either irbesartan (n = 49) or the beta(1)-adrenergic receptor blocker, atenolol ( n= 53)." | 9.10 | The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, KP, 2002) |
| " The aim of the LIFE-study was to establish whether treatment with the angiotensin-II AT 1-receptor antagonist, losartan, reduced cardiovascular events more effectively than treatment with the betablocker atenolol in patients with hypertension and left ventricular hypertrophy." | 9.10 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Pedersen, OL, 2003) |
| "We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol." | 9.10 | B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP, 2003) |
| "Patients with essential hypertension and echocardiographically diagnosed LVH were included in a double-blind study to receive treatment with either the angiotensin II type 1 receptor (AT1-receptor) antagonist irbesartan (n = 41), or the beta-1 adrenergic receptor blocker atenolol (n = 43) as monotherapy for 3 months." | 9.10 | Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol ( ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| "Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43)." | 9.10 | Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| "The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel-group study comparing the effects of losartan with those of atenolol on the reduction of cardiovascular complications in patients (n = 9,194) with essential hypertension and with electrocardiographically (ECG) documented left ventricular hypertrophy (LVH)." | 9.09 | Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2000) |
| "The present study was undertaken to clarify whether celiprolol and atenolol, beta1-selective beta blockers with and without intrinsic sympathomimetic activity (ISA), respectively, might improve ischemic damage in the isolated perfused hearts of spontaneously hypertensive rats (SHR), and whether long-term treatment with celiprolol may reduce left ventricular hypertrophy (LVH) in patients with essential hypertension." | 9.09 | Effect of celiprolol on cardiac hypertrophy in hypertension. ( Haneda, T; Honda, H; Kataoka, R; Kato, J; Kikuchi, K; Matsuhashi, H; Morimoto, H; Ogawa, Y; Takenaka, T; Tanazawa, S, 2000) |
| "The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of atenolol on the reduction of cardiovascular morbidity and mortality." | 9.09 | Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. ( Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM, 2000) |
| "In this multicenter, double-blind, active-controlled, randomized, parallel-group comparison, 66 patients with mild-to-moderate hypertension (sitting diastolic blood pressure, SDBP, 95-114 mm Hg) and LV mass index > 102 g/m2 for males and > 88 g/m2 for females were randomized to an initial treatment with 50 mg of either mibefradil or atenolol for 4 weeks." | 9.08 | A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients. ( Cifkova, R; Höglund, C; Lindberg, E; Mimran, A; Tenczer, J; Watt, A; Wilkins, MR, 1998) |
| "Antihypertensive treatment with the angiotensin II antagonist valsartan for 8 months produced a significant regression of LVH in predominantly previously untreated patients with essential hypertension." | 9.08 | Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. ( Harder, S; Kenedi, P; Rietbrock, N; Schmidt, A; Thürmann, PA, 1998) |
| "-Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension." | 9.08 | Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Hedner, T; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 1998) |
| "5 mg/day) on regression of left ventricular hypertrophy (LVH), an independent predictor of poor prognosis in hypertension, was compared by echocardiography to that of nifedipine (NFD, 40 mg/day), enalapril (ENL, 20 mg/day), atenolol (ATL, 100 mg/day), and hydrochlorothiazide (HCTZ, 25 mg/day) in four parallel double-blind studies in 151 hypertensive patients with a diastolic blood pressure between 95 and 120 mm Hg and a raised left ventricular mass index (LVMI) (mg/m2) (Devereux)." | 9.07 | Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. ( Amabile, G; Bory, M; De Luca, N; Denis, B; Imbs, JL; Lahiri, A; Marchegiano, R; Raftery, EB; Senior, R; Zannad, F, 1993) |
| "The objective of this study was to analyze the long-term hemodynamic effects of the calcium antagonist isradipine in mild hypertension compared with those of the beta 1-selective adrenoceptor antagonist atenolol, focusing in particular on the development of cardiac hypertrophy." | 9.07 | Beneficial effect of isradipine on the development of left ventricular hypertrophy in mild hypertension. ( Gleerup, G; Haedersdal, C; Mehlsen, J; Winther, K, 1993) |
| " Thus, the observed outcomes benefits favoring losartan may involve other possible mechanisms, including differential effects of losartan and atenolol on LVH regression, left atrial diameter, atrial fibrillation, brain natriuretic peptide, vascular structure, thrombus formation/platelet aggregation, serum uric acid, albuminuria, new-onset diabetes, and lipid metabolism." | 8.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| "Treatment of hypertensive patients with a losartan-based regimen was associated with greater regression of electrocardiographic (ECG) left ventricular hypertrophy (LVH) than atenolol-based therapy in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, independent of blood pressure (BP) changes." | 7.76 | Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2010) |
| "Treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy with losartan-based therapy is associated with lower incidence of diabetes mellitus and greater regression of hypertrophy than atenolol-based therapy." | 7.74 | In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) ( Dahlöf, B; Devereux, RB; Harris, KE; Jern, S; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2007) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 7.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) was a double-masked, randomized trial of losartan versus atenolol in 9193 patients with essential hypertension and left ventricular hypertrophy (LVH) ascertained by electrocardiography." | 7.73 | Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. ( Burke, TA; Carides, GW; Dahlöf, B; Dasbach, EJ; Jönsson, B; Lindholm, LH, 2005) |
| "The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study demonstrated a 13% relative risk reduction in the primary composite endpoint (myocardial infarction, stroke or death) for patients with hypertension and electrocardiographically diagnosed left ventricular hypertrophy (LVH) treated with losartan compared with atenolol." | 7.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| "Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group." | 6.75 | Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. ( Andersson, J; Boman, JH; Boman, K; Dahlöf, B; Olofsson, M, 2010) |
| "Electrocardiographic left ventricular hypertrophy (LVH) predicts cardiovascular morbidity and mortality, and regression of ECG LVH may predict improved prognosis in hypertensive patients." | 6.71 | Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. ( Aurup, P; Dahlof, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Nieminen, MS; Okin, PM; Snapinn, S, 2003) |
| "Thus, 115 hypertensive patients with left ventricular hypertrophy were randomized to receive double-blind irbesartan or atenolol, with additional therapy if needed." | 6.71 | Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Kahan, T; Lind, L; Malmqvist, K; Nyström, F; Ohman, KP, 2003) |
| "Hypertension is a major risk factor for morbidity and mortality." | 6.71 | Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K, 2004) |
| "Osteoprotegerin (OPG) is a secreted member of the tumor necrosis factor receptor family, and in previous studies has been shown to regulate osteoclast activity and differentiation." | 6.71 | A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA ( Brändström, H; Kahan, T; Kindmark, A; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; öHman, KP; Stiger, F, 2004) |
| "In hypertensive left ventricular hypertrophy (LVH), myocardial texture is altered by a disproportionate increase in fibrosis, but there is insufficient clinical evidence whether antihypertensive therapy or individual agents can induce regression of myocardial fibrosis." | 6.71 | Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. ( Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A, 2004) |
| "Patients with hypertension and left ventricular hypertrophy (n = 66) with a seated diastolic BP 90-115 mmHg (average of three measurements one minute apart by nurses)." | 6.70 | Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study. ( Kahan, T; Malmqvist, K; Nyström, F; Ohman, KP, 2002) |
| "Patients with hypertension have different types of left ventricular (LV) geometry, but the impact of blood pressure (BP) reduction on LV geometry change during antihypertensive treatment remains unclear." | 6.70 | Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Papademetriou, V; Rokkedal, J; Smith, G; Wachtell, K, 2002) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class." | 6.42 | Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004) |
| "Atenolol-treated MI rats had a significantly higher LVEDP, RAP and LVEDVI than did rats with untreated MI." | 5.29 | Effect of prolonged beta-adrenergic blockade induced by atenolol on left ventricular remodeling after acute myocardial infarction in the rat. ( Kawarabayashi, T; Nishikimi, T; Shimada, K; Takeda, T; Takeuchi, K, 1995) |
| "9 years follow-up in 9193 patients with hypertension randomized to losartan- or atenolol-based regimens." | 5.24 | Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension. ( Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM, 2017) |
| "Baseline estimated GFR (eGFR) and change in eGFR during follow-up were examined in relation to average on-treatment SBP in 8778 hypertensive patients with ECG left ventricular hypertrophy (LVH) randomly assigned to losartan- or atenolol-based treatment." | 5.22 | Impact of achieved systolic blood pressure on renal function in hypertensive patients. ( Devereux, RB; Kjeldsen, SE; Okin, PM, 2016) |
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 5.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| "Post hoc analysis of the Hypertension in Hemodialysis Patients Treated With Atenolol or Lisinopril (HDPAL) trial." | 5.20 | Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis. ( Agarwal, R; Georgianos, PI, 2015) |
| " The risk of new-onset AF was examined in relation to last in-treatment SBP before AF diagnosis or last in-study measurement in the absence of new AF in 8831 hypertensive patients with ECG left ventricular hypertrophy with no history of AF, in sinus rhythm on their baseline ECG, randomly assigned to losartan- or atenolol-based treatment." | 5.20 | Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Larstorp, AC; Okin, PM; Wachtell, K, 2015) |
| " atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events)." | 5.20 | Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K, 2015) |
| "8 years' losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke." | 5.20 | Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. ( Bang, CN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Hille, DA; Nieminen, MS; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K, 2015) |
| "Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations." | 5.19 | Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. ( Abraham, TN; Agarwal, R; Pappas, MK; Sinha, AD; Tegegne, GG, 2014) |
| "8 years randomized losartan- or atenolol-based antihypertensive treatment in the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study and classified as having ISH (n = 128) if systolic BP ≥ 160 mmHg and diastolic BP < 90 mmHg, or non-ISH divided into two groups by systolic BP ≥ 160 mmHg (non-ISH ≥ 160 mmHg) (n = 645) and systolic BP < 160 mm Hg (n = 100) (non-ISH < 160 mmHg), respectively." | 5.19 | Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study). ( Abdelhai, YM; Boman, K; Dahlöf, B; De Simone, G; Devereux, RB; Gerdts, E; Lønnebakken, MT; Mancusi, C; Wachtell, K, 2014) |
| " In multivariable Cox analyses, adjusting for randomized treatment, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum creatinine and glucose entered as standard covariates, and in-treatment non-HDL cholesterol, Cornell product left ventricular hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use as time-varying covariates, the lowest quartile of in-treatment HDL remained associated with a nearly 9-fold increased risk of new diabetes (hazard ratio 8." | 5.17 | In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM; Wiik, BP, 2013) |
| "In the Losartan Intervention For Endpoint reduction in Hypertension (LIFE) study, a double-blinded, randomized, parallel-group study, 9193 hypertensive patients with electrocardiogram (ECG)-documented left ventricular hypertrophy (LVH), randomized to once-daily losartan- or atenolol-based antihypertensive therapy were followed for a mean of 4." | 5.16 | Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Okin, PM; Olsen, MH; Reims, HM; Wachtell, K, 2012) |
| "Data from all patients with at least two echocardiographic examinations in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) echocardiographic substudy (n = 801); high-risk patients on losartan- vs." | 5.16 | Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Greve, AM; Lønnebakken, MT; Nieminen, MS; Okin, PM; Olsen, MH; Omvik, P; Palmieri, V; Wachtell, K, 2012) |
| "A total of 9,027 patients with hypertension and ECG-LVH and without a history of HF were randomized to losartan- or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension study." | 5.16 | Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| " We examined whether PP predicted new-onset AF in comparison with other blood pressure components in the Losartan Intervention For Endpoint reduction in hypertension study, a double-blind, randomized (losartan versus atenolol), parallel-group study, including 9193 patients with hypertension and electrocardiographic left ventricular hypertrophy." | 5.16 | Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| "Eight thousand one hundred ninety-four LIFE patients with hypertension and left ventricular hypertrophy with available baseline hemoglobin measurements were randomized to losartan- or atenolol-based treatment and followed for 4." | 5.14 | Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Narayan, P; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wedel, H, 2009) |
| "ECG strain was evaluated at baseline and after 1 year of therapy in 7409 hypertensive patients in the LIFE study (Losartan Intervention For End-point reduction in hypertension) treated in a blinded manner with atenolol- or losartan-based regimens." | 5.14 | Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). ( Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2009) |
| "The MPI was measured at baseline and after 48 weeks of antihypertensive treatment in 93 participants of the SILVHIA trial, where individuals with primary hypertension and left ventricular hypertrophy were randomized to double blind treatment with either irbesartan or atenolol." | 5.14 | The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SI ( Arnlöv, J; Kahan, T; Liljedahl, S; Lind, L, 2009) |
| "8 years of randomized losartan- or atenolol-based treatment within the echocardiographic substudy of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.14 | Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). ( Dahlöf, B; Devereux, RB; Franklin, S; Gerdts, E; Nieminen, M; Papademetriou, V; Rieck, A; Wachtell, K, 2009) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study compared effects of losartan-based versus atenolol-based therapy on cardiovascular events in 9193 patients with hypertension and LVH." | 5.14 | Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2009) |
| "It is unclear whether serum uric acid (SUA) is associated with development of new-onset diabetes (NOD) in patients with hypertension and left ventricular hypertrophy (LVH)." | 5.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| " Patients were treated with losartan- or atenolol-based regimens and followed with serial ECGs annually which were used to determine HR and ECG left ventricular hypertrophy by Cornell product and Sokolow-Lyon voltage criteria." | 5.13 | Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K, 2008) |
| "To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden." | 5.13 | Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| "The relation of ECG strain and albuminuria to new-onset HF was examined in 7,786 hypertensive patients with no history of HF, who were randomly assigned to treatment with losartan or atenolol." | 5.13 | Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Devereux, RB; Ibsen, H; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Oikarinen, L; Okin, PM; Olsen, MH; Toivonen, L; Viitasalo, M; Wachtell, K, 2008) |
| "8 years of randomized losartan- or atenolol-based treatment in the Losartan Intervention for Endpoint Reduction in Hypertension Echocardiography substudy." | 5.13 | Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Boman, K; Cramariuc, D; de Simone, G; Devereux, RB; Gerdts, E; Okin, PM; Wachtell, K, 2008) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 5.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 5.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "Hypertensive patients with electrocardiographic-left ventricular hypertrophy were randomized to losartan-based or atenolol-based treatment and followed for 4." | 5.13 | Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Jern, S; Kjeldsen, SE; Li, Z; Nieminen, MS; Okin, PM; Wachtell, K, 2008) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 5.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 5.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 5.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "Double-blind, randomized, parallel-group study conducted in 1995-2001 among 8831 men and women with hypertension, aged 55-80 years (median, 67 years), with electrocardiographic LVH by Cornell voltage-duration product or Sokolow-Lyon voltage, with no history of AF, without AF on the baseline electrocardiogram, and enrolled in the Losartan Intervention for Endpoint Reduction in Hypertension Study." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. ( Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Hille, DA; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K, 2006) |
| "In 204 patients with hypertension and left ventricular (LV) hypertrophy we measured serum concentration of carboxy-terminal telopeptide of type I procollagen (ICTP), carboxy-terminal propeptide of type I procollagen (PICP), amino-terminal propeptide of type III procollagen (PIIINP), amino-terminal propeptide of type I procollagen (PINP) and LV mass by echocardiography at baseline and annually during 4 years of losartan- or atenolol-based antihypertensive treatment; 185 patients completed the study." | 5.12 | Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. ( Bang, LE; Christensen, MK; Devereux, RB; Fossum, E; Hildebrandt, P; Ibsen, H; Kjeldsen, SE; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K; Wiinberg, N, 2006) |
| "LIFE was a randomized, double-blind trial comparing losartan-based and atenolol-based treatment regimens on the primary composite endpoint of death, myocardial infarction (MI), or stroke in 9193 patients aged 55-80 years with hypertension and left ventricular hypertrophy." | 5.12 | Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Hille, DA; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2007) |
| "The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study included 9193 patients 55 to 80 years of age with essential hypertension and ECG LV hypertrophy by gender-adjusted Cornell product (CP) (RaVL+SV(3) [+6 mm in women])." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Olsen, MH; Thygesen, K; Wachtell, K, 2007) |
| "The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, doubleblind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease (CVD)-related morbidity and mortality in 9193 patients with hypertension and left-ventricular hypertrophy (LVH)." | 5.12 | An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007) |
| "8479 hypertensive patients without history of heart failure who were randomly assigned to losartan or atenolol treatment." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM, 2007) |
| "Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.12 | The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. ( Brady, WE; Dahlöf, B; Devereux, RB; Fossum, E; Gleim, GW; Hille, DA; Julius, S; Kizer, JR; Kjeldsen, SE; Lyle, PA, 2007) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that losartan-based treatment reduced risk of the composite endpoint of cardiovascular death, stroke and myocardial infarction compared with atenolol-based treatment in patients with hypertension and left ventricular hypertrophy with similar office blood pressure (BP) reduction." | 5.12 | Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy. ( Bang, LE; Hildebrandt, PR; Ibsen, H; Larsen, J; Olsen, MH; Tuxen, C; Wachtell, K; Wiinberg, N, 2007) |
| "Patients with mild to moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta(1)-adrenergic receptor blocker atenolol (n = 49) as monotherapy." | 5.11 | Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. ( Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Syvänen, AC, 2004) |
| "The LIFE study compared losartan-based to atenolol-based therapy in 9,193 hypertensive patients with left ventricular hypertrophy (LVH)." | 5.11 | Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. ( Alderman, MH; Beevers, G; Dahlöf, B; Devereux, RB; Douglas, JG; Edelman, JM; Harris, KE; Julius, S; Kjeldsen, SE; Nesbitt, S; Randall, OS; Wright, JT, 2004) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study was designed to compare losartan- vs atenolol-based antihypertensive treatment on cardiovascular morbidity and mortality in a population of 9193 hypertensive patients with left ventricular hypertrophy (LVH)." | 5.11 | Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, GW; Dahlöf, B; Devereux, RB; Diener, HC; Edelman, JM; Krobot, K, 2004) |
| "Losartan prevented more cardiovascular complications than atenolol for the same reduction in blood pressure and have positive additional effects beyond blood pressure control in patients with hypertension and left ventricular hypertrophy." | 5.11 | [Treatment of hypertension in patients with left ventricular hypertrophy]. ( Bratland, B; Gerhardsen, G; Gisholt, K; Kjeldsen, SE; Omvik, P; Risanger, T; Smedsrud, T, 2004) |
| " We analysed paired echocardiograms in 500 men and 347 women enrolled in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study at baseline and after 12 months of antihypertensive treatment with either losartan or atenolol." | 5.11 | Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. ( Bella, JN; Dahlöf, B; Devereux, RB; Gerdts, E; Koren, MJ; Liu, JE; Nieminen, MS; Palmieri, V; Wachtell, K; Wright, JT; Zabalgoitia, M, 2004) |
| "We determined the association between the TGF-beta1 genotype and regression of LV mass in 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, randomized in a double-blind study to receive treatment for 48 weeks with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor blocker atenolol." | 5.11 | Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Billberger, K; Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaelsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2004) |
| " Baseline and year-1 ECGs and echocardiograms were assessed in 584 hypertensive patients with ECG LVH by Sokolow-Lyon or Cornell voltage-duration product criteria at entry into the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiographic substudy." | 5.11 | Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study. ( Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Liu, JE; Nieminen, MS; Oikarinen, L; Okin, PM; Wachtell, K, 2004) |
| "To assess the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment, we related age to clinical and echocardiographic findings before and after 4 years of antihypertensive treatment in a subset of 560 hypertensive patients without known concurrent disease in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which randomized patients to blinded losartan- or atenolol-based treatment." | 5.11 | Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). ( Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Roman, MJ; Smith, G; Wachtell, K, 2004) |
| "The Losartan Intervention For End point reduction in hypertension (LIFE) study showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke, and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; De Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| " The aim of this trial was to compare the effects of irbesartan versus atenolol on LVH in subjects with essential hypertension." | 5.11 | Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. ( Delles, C; Klingbeil, AU; Kolloch, RE; Krekler, M; Ludwig, M; Schmieder, RE; Schneider, MP; Stumpe, KO, 2004) |
| "We determined the preproendothelin-1 genotype using minisequencing in 102 patients with essential hypertension and LV hypertrophy verified by echocardiography, randomized in a double-blind fashion to treatment with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol." | 5.11 | Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2004) |
| "The aim of this study was to test whether these polymorphisms were associated with the change in heart rate or blood pressure in patients with essential hypertension and left ventricular (LV) hypertrophy treated with the beta1-adrenergic receptor blocker atenolol." | 5.11 | Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP, 2004) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 5.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left ventricular (LV) mass more than atenolol." | 5.11 | Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. ( Boman, K; Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004) |
| "Double-blind, randomized, parallel-group study conducted in 1995-2001 among 9193 men and women with hypertension aged 55 through 80 years (mean, 67 years), with electrocardiographic LVH by Cornell voltage-duration product or Sokolow-Lyon voltage criteria and enrolled in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study." | 5.11 | Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. ( Aurup, P; Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Snapinn, S; Wedel, H, 2004) |
| "Prospective cohort substudy of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) randomized clinical trial, conducted from 1995 to 2001." | 5.11 | Prognostic significance of left ventricular mass change during treatment of hypertension. ( Aurup, P; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Harris, K; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 5.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "Patients with mild to moderate primary hypertension and LV hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta1 adrenoreceptor blocker atenolol (n = 49)." | 5.11 | Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. ( Kahan, T; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Syvänen, AC, 2004) |
| "As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up." | 5.11 | Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy." | 5.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH)." | 5.11 | The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "In 183 patients with hypertension and electrocardiographic left ventricular (LV) hypertrophy, enrolled in the LIFE Study, we measured BP and serum Nt-proANP and Nt-proBNP by immunoassay after 2 weeks of placebo treatment and after 1, 2, 4, 6, 12, 24, 36 and 48 months of randomized treatment with losartan- or atenolol-based antihypertensive regimens." | 5.11 | Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. ( Bang, LE; Devereux, RB; Fossum, E; Hall, C; Hildebrandt, PR; Ibsen, H; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K, 2005) |
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "We conducted a subgroup analysis in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study to determine whether aspirin interacted with the properties of losartan, an angiotensin-II receptor antagonist." | 5.11 | The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fossum, E; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Moan, A; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "To compare the effects of the angiotensin II antagonist, losartan, with those of atenolol on left ventricular hypertrophy (LVH), blood pressure and neurohormone concentrations in hypertensive patients with LVH." | 5.10 | Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. ( Aurup, P; Barrios, V; Dahlof, B; Diez, J; Johansson, M; Nicholls, MG; Smith, RD; Yu, CM; Zanchetti, A, 2002) |
| "In the LIFE study, with a double-masked, randomized, parallel-group design, 9193 patients (46% men) with hypertension (mean age 67 years, average pressure 174/98 mmHg after placebo run-in) and electrocardiogram-documented left ventricular hypertrophy were randomly assigned to once-daily losartan- or atenolol-based antihypertensive treatment and followed for at least 4 years (mean 4." | 5.10 | Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. ( Aurup, P; Beevers, G; Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Snapinn, S; Wachtell, K; Wedel, H, 2002) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 5.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "One hundred and two patients with essential hypertension and left ventricular hypertrophy were allocated randomly to groups to receive double-blind treatment with either irbesartan (n = 49) or the beta(1)-adrenergic receptor blocker, atenolol ( n= 53)." | 5.10 | The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, KP, 2002) |
| " The aim of the LIFE-study was to establish whether treatment with the angiotensin-II AT 1-receptor antagonist, losartan, reduced cardiovascular events more effectively than treatment with the betablocker atenolol in patients with hypertension and left ventricular hypertrophy." | 5.10 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Pedersen, OL, 2003) |
| "We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol." | 5.10 | B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP, 2003) |
| "Cardiovascular morbidity and mortality are reduced by treatment with the angiotensin II AT(1)-receptor antagonist losartan compared with conventional treatment with the beta-blocker atenolol in patients with hypertension and electrocardiogram-defined left ventricular hypertrophy, many of whom had known vascular disease." | 5.10 | Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Helle Berg, S; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2003) |
| "We evaluated the influence of this polymorphism on the change in left ventricular mass index in 90 patients with essential hypertension and echocardiographically diagnosed left ventricular hypertrophy, randomised in a double-blind study to receive treatment with either the angiotensin II type I receptor antagonist irbesartan or the beta1-adrenoceptor blocker atenolol for 48 weeks." | 5.10 | Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy. ( Hallberg, P; Kahan, T; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2003) |
| "Patients with essential hypertension and echocardiographically diagnosed LVH were included in a double-blind study to receive treatment with either the angiotensin II type 1 receptor (AT1-receptor) antagonist irbesartan (n = 41), or the beta-1 adrenergic receptor blocker atenolol (n = 43) as monotherapy for 3 months." | 5.10 | Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol ( ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| "Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43)." | 5.10 | Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| "The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel-group study comparing the effects of losartan with those of atenolol on the reduction of cardiovascular complications in patients (n = 9,194) with essential hypertension and with electrocardiographically (ECG) documented left ventricular hypertrophy (LVH)." | 5.09 | Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2000) |
| " This study provides evidence that, in contrast to atenolol, quinapril, independent of blood pressure reduction, reduces left ventricular hypertrophy and improves left ventricular diastolic function in this population." | 5.09 | Comparison of quinapril versus atenolol: effects on blood pressure and cardiac mass after renal transplantation. ( Gerhardt, U; Hausberg, M; Hohage, H; Rahn, KH; Suwelack, B, 2000) |
| "The present study was undertaken to clarify whether celiprolol and atenolol, beta1-selective beta blockers with and without intrinsic sympathomimetic activity (ISA), respectively, might improve ischemic damage in the isolated perfused hearts of spontaneously hypertensive rats (SHR), and whether long-term treatment with celiprolol may reduce left ventricular hypertrophy (LVH) in patients with essential hypertension." | 5.09 | Effect of celiprolol on cardiac hypertrophy in hypertension. ( Haneda, T; Honda, H; Kataoka, R; Kato, J; Kikuchi, K; Matsuhashi, H; Morimoto, H; Ogawa, Y; Takenaka, T; Tanazawa, S, 2000) |
| "The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of atenolol on the reduction of cardiovascular morbidity and mortality." | 5.09 | Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. ( Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM, 2000) |
| "The Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA)." | 5.09 | Regression of left ventricular hypertrophy in human hypertension with irbesartan. ( Edner, M; Hägg, A; Held, C; Kahan, T; Lind, L; Malmqvist, K; Müller-Brunotte, R; Nyström, F; Ohman, KP; Osbakken, MD; Ostergern, J, 2001) |
| " To evaluate the effect of antihypertensive treatment on cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), we studied 46 hypertensive patients with LVH, divided into four groups randomly treated with enalapril, hydrochlorothiazide (HCTZ), atenolol, or verapamil (SR-V) for 6 months." | 5.09 | Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. ( Abrignani, MG; Barbagallo, M; Dominguez, LJ; Nardi, E; Novo, G; Novo, S; Strano, A, 2001) |
| "Patients with mild to moderate hypertension (diastolic blood pressure, 95 to 109 mm Hg) were randomly allocated to treatment with atenolol, captopril, clonidine, diltiazem, hydrochlorothiazide, or prazosin in a double-masked trial." | 5.08 | Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. ( Anderson, RJ; Gottdiener, JS; Massie, BM; Materson, BJ; Reda, DJ; Williams, DW, 1997) |
| "In this multicenter, double-blind, active-controlled, randomized, parallel-group comparison, 66 patients with mild-to-moderate hypertension (sitting diastolic blood pressure, SDBP, 95-114 mm Hg) and LV mass index > 102 g/m2 for males and > 88 g/m2 for females were randomized to an initial treatment with 50 mg of either mibefradil or atenolol for 4 weeks." | 5.08 | A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients. ( Cifkova, R; Höglund, C; Lindberg, E; Mimran, A; Tenczer, J; Watt, A; Wilkins, MR, 1998) |
| "Antihypertensive treatment with the angiotensin II antagonist valsartan for 8 months produced a significant regression of LVH in predominantly previously untreated patients with essential hypertension." | 5.08 | Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. ( Harder, S; Kenedi, P; Rietbrock, N; Schmidt, A; Thürmann, PA, 1998) |
| "-Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension." | 5.08 | Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Hedner, T; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 1998) |
| "5 mg/day) on regression of left ventricular hypertrophy (LVH), an independent predictor of poor prognosis in hypertension, was compared by echocardiography to that of nifedipine (NFD, 40 mg/day), enalapril (ENL, 20 mg/day), atenolol (ATL, 100 mg/day), and hydrochlorothiazide (HCTZ, 25 mg/day) in four parallel double-blind studies in 151 hypertensive patients with a diastolic blood pressure between 95 and 120 mm Hg and a raised left ventricular mass index (LVMI) (mg/m2) (Devereux)." | 5.07 | Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. ( Amabile, G; Bory, M; De Luca, N; Denis, B; Imbs, JL; Lahiri, A; Marchegiano, R; Raftery, EB; Senior, R; Zannad, F, 1993) |
| "The objective of this study was to analyze the long-term hemodynamic effects of the calcium antagonist isradipine in mild hypertension compared with those of the beta 1-selective adrenoceptor antagonist atenolol, focusing in particular on the development of cardiac hypertrophy." | 5.07 | Beneficial effect of isradipine on the development of left ventricular hypertrophy in mild hypertension. ( Gleerup, G; Haedersdal, C; Mehlsen, J; Winther, K, 1993) |
| " Thus, the observed outcomes benefits favoring losartan may involve other possible mechanisms, including differential effects of losartan and atenolol on LVH regression, left atrial diameter, atrial fibrillation, brain natriuretic peptide, vascular structure, thrombus formation/platelet aggregation, serum uric acid, albuminuria, new-onset diabetes, and lipid metabolism." | 4.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| "The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy." | 4.82 | Implications of the LIFE trial. ( Lim, HS; Lip, GY; Nadar, S, 2003) |
| "Risk of incident stroke was examined in relation to abnormal PTFV1 on a baseline ECG in 7778 hypertensive patients with ECG left ventricular hypertrophy, no history of atrial fibrillation, in sinus rhythm on their baseline ECG with no incident atrial fibrillation during follow-up, who were randomly assigned to losartan-based or atenolol-based treatment." | 3.83 | Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy. ( Devereux, RB; Kamel, H; Kjeldsen, SE; Okin, PM, 2016) |
| "Patients with echocardiographic left ventricular hypertrophy at baseline (n = 124) showed greater reduction of left ventricular mass index with Per/Ind (-11." | 3.80 | [Arterial stiffness, wave reflections and myocardial protection: the REASON project]. ( London, GM, 2003) |
| "Treatment of hypertensive patients with a losartan-based regimen was associated with greater regression of electrocardiographic (ECG) left ventricular hypertrophy (LVH) than atenolol-based therapy in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, independent of blood pressure (BP) changes." | 3.76 | Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2010) |
| "We evaluated the effects of nebivolol, a third-generation highly selective [beta]-blocker with additional vasodilating activity, versus the traditional [beta]-blocker atenolol in controlling functional and morphological cardiovascular damage in a rat model of metabolic syndrome." | 3.76 | Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats. ( Angerosa, M; Cao, G; Dominici, F; Giani, J; Munoz, M; Rivas, C; Toblli, J, 2010) |
| "In 9193 hypertensive patients included in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, we measured urine albumin/creatinine ratio (UACR), LV hypertrophy by electrocardiography, serum high-density lipoprotein (HDL) cholesterol, and blood pressure after 2 weeks of placebo treatment and yearly during 5 years of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen." | 3.76 | Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study. ( Dahlöf, B; Devereux, RB; Kjeldsen, SE; Okin, PM; Olsen, MH; Søraas, CL; Tønnessen, T; Wachtell, K, 2010) |
| "Treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy with losartan-based therapy is associated with lower incidence of diabetes mellitus and greater regression of hypertrophy than atenolol-based therapy." | 3.74 | In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) ( Dahlöf, B; Devereux, RB; Harris, KE; Jern, S; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2007) |
| "8 years losartan- or atenolol-based treatment in the Losartan Intervention for Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 3.74 | Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). ( Cramariuc, D; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Wachtell, K, 2008) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 3.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) was a double-masked, randomized trial of losartan versus atenolol in 9193 patients with essential hypertension and left ventricular hypertrophy (LVH) ascertained by electrocardiography." | 3.73 | Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. ( Burke, TA; Carides, GW; Dahlöf, B; Dasbach, EJ; Jönsson, B; Lindholm, LH, 2005) |
| "In 6679 hypertensive patients included in the LIFE study, we measured UACR, left ventricular hypertrophy by electrocardiography, serum cholesterol, plasma glucose and blood pressure after 2 weeks of placebo treatment and again after 1 year of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen." | 3.73 | Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Oikarinen, L; Okin, PM; Olsen, MH; Wachtell, K, 2006) |
| "The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study demonstrated a 13% relative risk reduction in the primary composite endpoint (myocardial infarction, stroke or death) for patients with hypertension and electrocardiographically diagnosed left ventricular hypertrophy (LVH) treated with losartan compared with atenolol." | 3.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| "In a prospective follow-up study we screened 970 hypertensive patients of Caucasian descent for the Gly16Arg, Gln27Glu, and Thr164Ile beta(2)AR polymorphisms and left ventricular echocardiographic hypertrophy and assigned selected patients to enalapril or atenolol to assess left ventricular hypertrophy regression after 2-year follow-up." | 3.73 | Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension. ( Cipolletta, E; De Luca, N; Di Renzo, G; Iaccarino, G; Iovino, GL; Izzo, R; Lanni, F; Priante, O; Rozza, F; Sorriento, D; Trimarco, B; Trimarco, V, 2006) |
| " The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study provides additional data to support the use of the ACE inhibitors to lower the risk of stroke among patients with hypertension and vascular diseases." | 3.72 | New strategies for prevention of ischemic stroke: the LIFE study. ( Adams, HP, 2003) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "The effects of propranolol and atenolol were investigated on arterial hypertension, cardiomyocyte hypertrophy, and ventricular ischaemic lesions induced by an 8-week treatment with the nitric oxide synthase inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME; 20 mg/rat per day) in Wistar rats." | 3.71 | Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis. ( Antunes, E; de Azevedo, AP; De Luca, IM; De Nucci, G; De Oliveira, CF; Pacca, SR, 2002) |
| "Despite regression of left ventricular hypertrophy, there was no associated improvement in diastolic function." | 2.79 | Long-term antihypertensive treatment fails to improve E/e' despite regression of left ventricular mass: an Anglo-Scandinavian cardiac outcomes trial substudy. ( Baksi, AJ; Barron, AJ; Fitzgerald, D; Hughes, AD; Jabbour, RJ; Mayet, J; O'Brien, E; Poulter, N; Sever, P; Sharp, A; Stanton, A; Surendran, P; Thom, S, 2014) |
| "Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group." | 2.75 | Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. ( Andersson, J; Boman, JH; Boman, K; Dahlöf, B; Olofsson, M, 2010) |
| "Patients with hypertension and left ventricular hypertrophy (LVH) are at increased risk of cardiovascular complications and the current guidelines recommend echocardiography for determination of left ventricular mass." | 2.74 | [Echocardiography of left ventricular mass in patients with essential hypertension]. ( Buus, NH; Christensen, KL; Fenger-Grøn, M, 2009) |
| "Aortic stiffness and left ventricular hypertrophy (LVH) are predictors of mortality in hemodialysis (HD) patients." | 2.71 | Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. ( Adda, H; Guerin, AP; London, GM; Marchais, SJ; Metivier, F; Pannier, B, 2003) |
| "Electrocardiographic left ventricular hypertrophy (LVH) predicts cardiovascular morbidity and mortality, and regression of ECG LVH may predict improved prognosis in hypertensive patients." | 2.71 | Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. ( Aurup, P; Dahlof, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Nieminen, MS; Okin, PM; Snapinn, S, 2003) |
| "Thus, 115 hypertensive patients with left ventricular hypertrophy were randomized to receive double-blind irbesartan or atenolol, with additional therapy if needed." | 2.71 | Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Kahan, T; Lind, L; Malmqvist, K; Nyström, F; Ohman, KP, 2003) |
| "Hypertension is a major risk factor for morbidity and mortality." | 2.71 | Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K, 2004) |
| "Osteoprotegerin (OPG) is a secreted member of the tumor necrosis factor receptor family, and in previous studies has been shown to regulate osteoclast activity and differentiation." | 2.71 | A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA ( Brändström, H; Kahan, T; Kindmark, A; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; öHman, KP; Stiger, F, 2004) |
| "In hypertensive left ventricular hypertrophy (LVH), myocardial texture is altered by a disproportionate increase in fibrosis, but there is insufficient clinical evidence whether antihypertensive therapy or individual agents can induce regression of myocardial fibrosis." | 2.71 | Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. ( Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A, 2004) |
| "Patients with hypertension and left ventricular hypertrophy (n = 66) with a seated diastolic BP 90-115 mmHg (average of three measurements one minute apart by nurses)." | 2.70 | Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study. ( Kahan, T; Malmqvist, K; Nyström, F; Ohman, KP, 2002) |
| "Patients with hypertension have different types of left ventricular (LV) geometry, but the impact of blood pressure (BP) reduction on LV geometry change during antihypertensive treatment remains unclear." | 2.70 | Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Papademetriou, V; Rokkedal, J; Smith, G; Wachtell, K, 2002) |
| "Left ventricular hypertrophy is very frequent when determined by echocardiography and all three drugs produced regression of left ventricular hypertrophy in a different way with respect to left ventricle geometry, an effect which could have potential therapeutic implications." | 2.68 | [Effect of 3 hypertensive++ agents on ventricular geometry and function]. ( Gómez Pajuelo, C; Gómez Sánchez, MA; Lombera Romero, F; Marín Ruiz, R; Sáenz de la Calzada, C; Sanz Julve, M; Tascón Pérez, J, 1995) |
| "It is now recognized that left ventricular hypertrophy (LVH), often associated with hypertension, is itself a risk factor for coronary disease in the elderly." | 2.67 | Left ventricular mass regression in elderly hypertensives. ( Gerstenblith, G, 1992) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class." | 2.42 | Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004) |
| "She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome." | 2.41 | Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium. ( Hattori, K; Hirakawa, Y; Ichihashi, R; Kei, M; Matsubara, K; Saburi, Y; Sakurai, H; Tsukamoto, H; Yokouchi, K, 2000) |
| "In the case of HOCM, left ventricular hypertrophy is the primary process." | 1.37 | [Mitral valve dysplasia in a cat causing reversible left ventricular hypertrophy and dynamic outflow tract obstruction]. ( Kuijpers, NW; Szatmári, V, 2011) |
| "Atenolol-treated MI rats had a significantly higher LVEDP, RAP and LVEDVI than did rats with untreated MI." | 1.29 | Effect of prolonged beta-adrenergic blockade induced by atenolol on left ventricular remodeling after acute myocardial infarction in the rat. ( Kawarabayashi, T; Nishikimi, T; Shimada, K; Takeda, T; Takeuchi, K, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (9.36) | 18.2507 |
| 2000's | 150 (73.89) | 29.6817 |
| 2010's | 33 (16.26) | 24.3611 |
| 2020's | 1 (0.49) | 2.80 |
| Authors | Studies |
|---|---|
| Feinberg, JB | 1 |
| Nielsen, EE | 1 |
| Kjeldsen, SE | 65 |
| Devereux, RB | 88 |
| Gerdts, E | 24 |
| Wachtell, K | 53 |
| Olsen, MH | 30 |
| Okin, PM | 39 |
| Hille, DA | 17 |
| Wiik, BP | 2 |
| Lindholm, LH | 36 |
| Dahlöf, B | 85 |
| Jekell, A | 1 |
| Malmqvist, K | 19 |
| Wallén, NH | 1 |
| Mörtsell, D | 2 |
| Kahan, T | 23 |
| Barron, AJ | 1 |
| Hughes, AD | 1 |
| Sharp, A | 1 |
| Baksi, AJ | 1 |
| Surendran, P | 1 |
| Jabbour, RJ | 1 |
| Stanton, A | 1 |
| Poulter, N | 1 |
| Fitzgerald, D | 1 |
| Sever, P | 2 |
| O'Brien, E | 2 |
| Thom, S | 1 |
| Mayet, J | 1 |
| Agarwal, R | 2 |
| Sinha, AD | 1 |
| Pappas, MK | 1 |
| Abraham, TN | 1 |
| Tegegne, GG | 1 |
| Mancusi, C | 2 |
| De Simone, G | 6 |
| Abdelhai, YM | 1 |
| Lønnebakken, MT | 3 |
| Boman, K | 14 |
| Bang, CN | 2 |
| Aurigemma, GP | 2 |
| Køber, L | 1 |
| Georgianos, PI | 1 |
| Larstorp, AC | 5 |
| Vishram, JK | 1 |
| Ibsen, H | 41 |
| Mancia, G | 2 |
| Rothwell, PM | 1 |
| Roman, MJ | 2 |
| Palmieri, V | 10 |
| Nieminen, MS | 43 |
| Papademetriou, V | 8 |
| Kamel, H | 1 |
| Midtbø, H | 1 |
| Avanza, AC | 1 |
| Mansur, AP | 1 |
| Ramires, JA | 1 |
| Beevers, G | 12 |
| de Faire, U | 18 |
| Fyhrquist, F | 18 |
| Lederballe-Pedersen, O | 17 |
| Narayan, P | 1 |
| Omvik, P | 21 |
| Oparil, S | 19 |
| Wedel, H | 17 |
| Oikarinen, L | 10 |
| Viitasalo, M | 7 |
| Toivonen, L | 7 |
| Edelman, JM | 20 |
| Pasquale, F | 1 |
| Tomé-Esteban, MT | 1 |
| Morgagni, R | 1 |
| Elliott, P | 1 |
| Liljedahl, S | 1 |
| Lind, L | 15 |
| Arnlöv, J | 1 |
| Franklin, S | 1 |
| Rieck, A | 1 |
| Nieminen, M | 1 |
| Morin, DP | 1 |
| John, M | 1 |
| Gopinathannair, R | 1 |
| Sullivan, RM | 1 |
| Olshansky, B | 1 |
| Julius, S | 32 |
| Boman, JH | 1 |
| Andersson, J | 1 |
| Olofsson, M | 1 |
| Christensen, KL | 1 |
| Fenger-Grøn, M | 1 |
| Buus, NH | 1 |
| Lyle, PA | 9 |
| Snapinn, SM | 7 |
| Toblli, J | 1 |
| Cao, G | 1 |
| Rivas, C | 1 |
| Munoz, M | 1 |
| Giani, J | 1 |
| Dominici, F | 1 |
| Angerosa, M | 1 |
| Søraas, CL | 1 |
| Tønnessen, T | 1 |
| Høieggen, A | 4 |
| Lindholm, L | 1 |
| Rokkedal, JE | 1 |
| Verdecchia, P | 1 |
| Angeli, F | 1 |
| Mazzotta, G | 1 |
| Reboldi, G | 1 |
| Kuijpers, NW | 1 |
| Szatmári, V | 1 |
| Silventoinen, K | 1 |
| Saijonmaa, O | 1 |
| Kontula, K | 1 |
| Os, I | 3 |
| Ariansen, I | 2 |
| Reims, HM | 5 |
| Gjesdal, K | 2 |
| Greve, AM | 1 |
| Bella, JN | 6 |
| Nyström, F | 12 |
| Ohman, KP | 10 |
| Zanchetti, A | 3 |
| Diez, J | 3 |
| Nicholls, MG | 2 |
| Yu, CM | 1 |
| Barrios, V | 2 |
| Aurup, P | 8 |
| Smith, RD | 2 |
| Johansson, M | 1 |
| Borch-Johnsen, K | 5 |
| Kristianson, K | 12 |
| Snapinn, S | 7 |
| Malik, RA | 1 |
| Edelman, J | 1 |
| Hallberg, P | 7 |
| Karlsson, J | 8 |
| Kurland, L | 11 |
| Melhus, H | 12 |
| Dominiak, P | 1 |
| Zidek, W | 2 |
| Edner, M | 4 |
| Bergfeldt, L | 1 |
| Rokkedal, J | 8 |
| Smith, G | 3 |
| Karpov, IuA | 1 |
| Adams, HP | 1 |
| Schmieder, RE | 2 |
| Schneider, MP | 2 |
| Pedersen, OL | 1 |
| Michaëlsson, K | 5 |
| Messerli, FH | 2 |
| London, GM | 3 |
| Marchais, SJ | 1 |
| Guerin, AP | 1 |
| Metivier, F | 1 |
| Adda, H | 1 |
| Pannier, B | 1 |
| Fujino, T | 2 |
| Hasebe, N | 2 |
| Kawabe, J | 2 |
| Fujita, M | 2 |
| Fukuzawa, J | 1 |
| Tobise, K | 2 |
| Kikuchi, K | 3 |
| Nadar, S | 1 |
| Lim, HS | 1 |
| Lip, GY | 2 |
| Liebson, PR | 1 |
| Jern, S | 11 |
| Connolly, DJ | 1 |
| Boswood, A | 1 |
| Harris, KE | 11 |
| Helle Berg, S | 1 |
| Baumgart, P | 2 |
| Sidorenko, BA | 1 |
| Ugriumova, MO | 1 |
| Liljedahl, U | 6 |
| Syvänen, AC | 6 |
| Minami, N | 1 |
| Yoshikawa, T | 1 |
| Kataoka, H | 1 |
| Mori, N | 1 |
| Nagasaka, M | 1 |
| Kurosawa, H | 1 |
| Kanazawa, M | 1 |
| Kohzuki, M | 1 |
| Ong, HT | 1 |
| Alderman, MH | 1 |
| Douglas, JG | 1 |
| Nesbitt, S | 1 |
| Randall, OS | 1 |
| Wright, JT | 2 |
| Burke, TA | 2 |
| Krobot, K | 1 |
| Carides, GW | 3 |
| Diener, HC | 1 |
| Liakishev, AA | 1 |
| Bratland, B | 1 |
| Gerhardsen, G | 1 |
| Gisholt, K | 1 |
| Risanger, T | 1 |
| Smedsrud, T | 1 |
| Liu, JE | 2 |
| Koren, MJ | 1 |
| Zabalgoitia, M | 1 |
| Billberger, K | 1 |
| Fossum, E | 7 |
| Brady, WE | 3 |
| Klingbeil, AU | 1 |
| Delles, C | 1 |
| Ludwig, M | 1 |
| Kolloch, RE | 1 |
| Krekler, M | 1 |
| Stumpe, KO | 1 |
| Brändström, H | 1 |
| Stiger, F | 1 |
| Kindmark, A | 1 |
| Tuxen, C | 4 |
| Bang, LE | 4 |
| Hall, C | 3 |
| Hildebrandt, P | 2 |
| de Luca, N | 4 |
| Asmar, RG | 1 |
| O'Rourke, MF | 3 |
| Safar, ME | 3 |
| Ciulla, MM | 1 |
| Paliotti, R | 1 |
| Esposito, A | 1 |
| López, B | 2 |
| Gilles, L | 1 |
| Magrini, F | 1 |
| Mogensen, CE | 2 |
| Wan, Y | 3 |
| Mallion, JM | 1 |
| Rahn, KH | 2 |
| Trimarco, B | 3 |
| Romero, R | 1 |
| De Leeuw, PW | 1 |
| Hitzenberger, G | 1 |
| Battegay, E | 1 |
| Duprez, D | 1 |
| Du, XJ | 1 |
| Fang, L | 1 |
| Gao, XM | 1 |
| Kiriazis, H | 1 |
| Feng, X | 1 |
| Hotchkin, E | 1 |
| Finch, AM | 1 |
| Chaulet, H | 1 |
| Graham, RM | 1 |
| Harris, K | 1 |
| Kizer, JR | 3 |
| Pulcrano, M | 1 |
| Palmieri, EA | 1 |
| Pagano, L | 1 |
| Tauchmanova, L | 1 |
| Rossi, A | 1 |
| Fazio, S | 1 |
| Lombardi, G | 1 |
| Biondi, B | 1 |
| Müller-Brunotte, R | 3 |
| Hornestam, B | 2 |
| Lehto, M | 2 |
| Slotwiner, DJ | 1 |
| Hildebrandt, PR | 3 |
| Agabiti-Rosei, E | 1 |
| Muiesan, ML | 1 |
| Reid, J | 1 |
| Salvetti, A | 2 |
| Tang, R | 1 |
| Hennig, M | 1 |
| Baurecht, H | 1 |
| Parati, G | 1 |
| Jönsson, B | 2 |
| Dasbach, EJ | 1 |
| Moan, A | 1 |
| Anis, AH | 1 |
| Sun, H | 1 |
| Singh, S | 1 |
| Woolcott, J | 1 |
| Nosyk, B | 1 |
| Brisson, M | 1 |
| Xie, HH | 1 |
| Shen, FM | 1 |
| Zhang, XF | 1 |
| Jiang, YY | 1 |
| Su, DF | 1 |
| Nielsen, OW | 1 |
| Wergeland, R | 1 |
| Ring, M | 1 |
| Cooper-Dehoff, R | 1 |
| Cohen, JD | 2 |
| Bakris, GL | 1 |
| Erdine, S | 1 |
| Hewkin, AC | 1 |
| Kupfer, S | 1 |
| Pepine, CJ | 1 |
| Björnstad, H | 2 |
| Lund-Jhansen, P | 1 |
| Davidsen, ES | 1 |
| Christensen, MK | 1 |
| Wiinberg, N | 2 |
| Iaccarino, G | 1 |
| Izzo, R | 1 |
| Trimarco, V | 1 |
| Cipolletta, E | 1 |
| Lanni, F | 1 |
| Sorriento, D | 1 |
| Iovino, GL | 1 |
| Rozza, F | 1 |
| Priante, O | 1 |
| Di Renzo, G | 1 |
| Otterstad, JE | 1 |
| Held, C | 2 |
| Thygesen, K | 1 |
| Boersma, C | 1 |
| Atthobari, J | 1 |
| Voors, AA | 1 |
| Postma, MJ | 1 |
| Smebye, ML | 1 |
| Iversen, EK | 1 |
| Flaa, A | 1 |
| Chattopadhyay, A | 1 |
| Castellano, JM | 1 |
| González, A | 1 |
| Barba, J | 1 |
| Gleim, GW | 1 |
| Lindgren, P | 1 |
| Buxton, M | 1 |
| Poulter, NR | 1 |
| Sever, PS | 1 |
| Narkiewicz, K | 1 |
| Hedner, T | 3 |
| Larsen, J | 1 |
| Cramariuc, D | 2 |
| Franco, V | 1 |
| Manhem, K | 1 |
| Escobar, C | 1 |
| Tomás, JP | 1 |
| Calderon, A | 1 |
| Echarri, R | 1 |
| Hashemi, N | 1 |
| Li, Z | 1 |
| Senior, R | 1 |
| Imbs, JL | 1 |
| Bory, M | 1 |
| Amabile, G | 1 |
| Denis, B | 1 |
| Zannad, F | 1 |
| Marchegiano, R | 1 |
| Lahiri, A | 1 |
| Raftery, EB | 1 |
| González-Juanatey, JR | 1 |
| Pose Reino, A | 1 |
| Amaro Cendón, A | 1 |
| García Acuña, JM | 1 |
| Castelo Fuentes, V | 1 |
| Calvo Gómez, C | 1 |
| de la Peña, MG | 1 |
| Gómez Pajuelo, C | 1 |
| Gómez Sánchez, MA | 1 |
| Marín Ruiz, R | 1 |
| Lombera Romero, F | 1 |
| Sanz Julve, M | 1 |
| Tascón Pérez, J | 1 |
| Sáenz de la Calzada, C | 1 |
| Shimada, K | 1 |
| Nishikimi, T | 1 |
| Kawarabayashi, T | 1 |
| Takeuchi, K | 2 |
| Takeda, T | 1 |
| Ranieri, G | 1 |
| Taddei, S | 1 |
| Filitti, V | 1 |
| Andriani, A | 1 |
| Bonfantino, MV | 1 |
| Lamontanara, G | 1 |
| De Cesaris, R | 1 |
| Mehlsen, J | 1 |
| Gleerup, G | 1 |
| Haedersdal, C | 1 |
| Winther, K | 1 |
| Gottdiener, JS | 2 |
| Reda, DJ | 1 |
| Massie, BM | 1 |
| Materson, BJ | 1 |
| Williams, DW | 1 |
| Anderson, RJ | 1 |
| Devereux, R | 1 |
| Kjeldsen, S | 1 |
| Kribben, A | 1 |
| Anlauf, M | 1 |
| Distler, A | 1 |
| Gärtner, H | 1 |
| Holzgreve, H | 1 |
| Michaelis, J | 1 |
| Röcker, L | 1 |
| Schäfers, R | 1 |
| Philipp, U | 1 |
| Wellek, S | 1 |
| Philipp, T | 1 |
| Ofili, EO | 1 |
| St Vrain, JA | 1 |
| Pearson, A | 1 |
| Martin, TJ | 1 |
| Uy, ND | 1 |
| Castello, R | 1 |
| Labovitz, AJ | 1 |
| Höglund, C | 1 |
| Cifkova, R | 1 |
| Mimran, A | 1 |
| Tenczer, J | 1 |
| Watt, A | 1 |
| Wilkins, MR | 1 |
| Lindberg, E | 1 |
| Higashiyama, S | 1 |
| Taniguchi, N | 1 |
| Thürmann, PA | 3 |
| Kenedi, P | 1 |
| Schmidt, A | 1 |
| Harder, S | 1 |
| Rietbrock, N | 1 |
| Suwelack, B | 1 |
| Gerhardt, U | 1 |
| Hausberg, M | 1 |
| Hohage, H | 1 |
| Haneda, T | 1 |
| Ogawa, Y | 1 |
| Kato, J | 1 |
| Matsuhashi, H | 1 |
| Morimoto, H | 1 |
| Honda, H | 1 |
| Takenaka, T | 1 |
| Tanazawa, S | 1 |
| Kataoka, R | 1 |
| Sakurai, H | 1 |
| Kei, M | 1 |
| Matsubara, K | 1 |
| Yokouchi, K | 1 |
| Hattori, K | 1 |
| Ichihashi, R | 1 |
| Hirakawa, Y | 1 |
| Tsukamoto, H | 1 |
| Saburi, Y | 1 |
| Hägg, A | 3 |
| Osbakken, MD | 1 |
| Ostergern, J | 1 |
| Novo, S | 1 |
| Abrignani, MG | 1 |
| Novo, G | 1 |
| Nardi, E | 1 |
| Dominguez, LJ | 1 |
| Strano, A | 1 |
| Barbagallo, M | 1 |
| Pacca, SR | 1 |
| de Azevedo, AP | 1 |
| De Oliveira, CF | 1 |
| De Luca, IM | 1 |
| De Nucci, G | 1 |
| Antunes, E | 1 |
| Schiffrin, EL | 1 |
| Park, JB | 1 |
| Pu, Q | 1 |
| Giles, TD | 1 |
| Aalto, T | 1 |
| Ohman, P | 2 |
| Einecke, D | 1 |
| Nilsson, P | 1 |
| Spencer, CG | 1 |
| Gurney, D | 1 |
| Blann, AD | 1 |
| Beevers, DG | 1 |
| Gerstenblith, G | 1 |
| Wheeldon, NM | 1 |
| Pringle, TH | 1 |
| Lipworth, BJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy[NCT00389168] | Phase 2/Phase 3 | 115 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| Hypertension in Hemodialysis Patients[NCT00582114] | Phase 3 | 200 participants (Actual) | Interventional | 2005-08-31 | Terminated (stopped due to Stopped by data safety monitoring board) | ||
| Assessment of Prolonged Paced QRS Duration as a Marker of Sudden Cardiac Death in Subjects With Implantable Cardioverter-defibrillators[NCT01948206] | 100 participants (Actual) | Observational | 2013-10-31 | Terminated (stopped due to Ran out of funds) | |||
| Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.[NCT00456963] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2007-09-30 | Terminated (stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.) | ||
| Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321] | 100 participants (Anticipated) | Observational | 2014-01-31 | Active, not recruiting | |||
| Angiotensin Blocking Effect of Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG: a Prospective, Multicenter, Observational Registry[NCT03219632] | 72 participants (Actual) | Observational [Patient Registry] | 2012-06-05 | Completed | |||
| Characterization of Myocardial Interstitial Fibrosis and Cardiomyocyte Hypertrophy by Cardiac MRI In Heart Failure: Implication on Early Remodeling and on the Transition to Heart Failure[NCT03084679] | 90 participants (Anticipated) | Interventional | 2017-11-01 | Recruiting | |||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151] | Phase 2 | 138 participants (Anticipated) | Interventional | 2021-02-08 | Recruiting | ||
| Double-blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-hypertensive Pre-diabetic Subjects[NCT00388388] | Phase 2 | 1 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Few subjects recruited, sponsor withdrew support.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Difference in Diastolic Blood Pressure. Repeated measures multivariable analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Atenolol | -16.3 |
| Irbesartan | -18.8 |
Changes in common carotid artery intima-media thickness, assessed by ultrasonography. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm (Mean) |
|---|---|
| Atenolol | 0.03 |
| Irbesartan | -0.01 |
Safety was assessed by non-directed questions, and all observed and volunteered adverse events were recorded at each study visit. Serious adverse events were defined by, and reported according to the regulations of good clinical practice (GCP). none were considered related to the study medication. (NCT00389168)
Timeframe: Treatment period was baseline to 48 weeks
| Intervention | Participants (Number) |
|---|---|
| Atenolol | 5 |
| Irbesartan | 5 |
Repeated measures multivariate analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks. Data are presented as left ventricular mass in gram (g) indexed for body mass index (in m^2). (NCT00389168)
Timeframe: Baseline and 48 weeks
| Intervention | g/m^2 (Mean) | ||
|---|---|---|---|
| 12 weeks | 24 weeks | 48 weeks | |
| Atenolol | -1 | -6 | -14 |
| Irbesartan | -9 | -14 | -26 |
Venous plasma concentrations of angiotensin II were measured in order to study the possible associations between the activity of the renin-angiotensin-aldosteone system and changes in left ventricular mass. Further analyses of other components of the renin-angiotensin-aldosterone system and of other hormonal system (e.g. the sympathetic nervous system) have also been performed and published. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Data were log-transformed to avoid skewness before statistical evaluation. However, tabular data are given as mean values with 95% confidence to improve readability. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | pmol/L (Mean) | ||
|---|---|---|---|
| Weel 12 | Week 24 | Week 48 | |
| Atenolol | -1.0 | -0.8 | -0.2 |
| Irbesartan | 3.0 | 3.3 | 10.0 |
Changes in left ventricular diastolic function from baseline to week 48 will be evaluated as the difference in E/A ratio. Conventional pulsed wave Doppler echocardiography was used for recordings of mitral inflow in. The peak of early (E) and late (A) mitral flow velocities were measured, and the E/A-ratio was calculated. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Some echocardiographic recordings at some time point may be of insufficient quality or missing, and the number of observations may not always correspond to the total number of participants at all time points. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | ratio (Mean) | ||
|---|---|---|---|
| Week 12 | Week 24 | Week 48 | |
| Atenolol | 0.18 | 0.16 | 0.13 |
| Irbesartan | 0.10 | 0.04 | 0.10 |
Cardiovascular events were counted by subject and included the following: myocardial infarction (MI), stroke, hospitalization for congestive heart failure (CHF), hospitalized angina, arrhythmias, cardiac arrest, coronary revascularization and heart valve replacement. Adverse events reported are those during the course of 12 months of participation in the trial. All serious adverse events were adjudicated by R.A. and A.D.S. who were masked to the drug assignment at the time of adjudication. The duration of participation in the study per subject, which according to the trial design could be up to 12 months, was determined. The cardiovascular event rate was calculated by treatment group assignment. Incidence rate ratio (IRR) by treatment was then determined along with the 95% confidence intervals (95% CIs). As a post hoc analysis, we also determined the narrower definition of cardiovascular events per group that included MI, stroke, CHF, or cardiovascular death. (NCT00582114)
Timeframe: 1 yr
| Intervention | events/100 patient-years (Number) | |||
|---|---|---|---|---|
| Incidence rate, cardiovasular events | Incidence rate, combined MI, stroke, CHF, CV death | Incidence rate, congest heart failure | Incidence rate, all-cause hospitalizations | |
| Atenolol | 24.6 | 13.5 | 6.2 | 89.9 |
| Lisinopril | 58 | 31 | 20.2 | 144.3 |
The primary outcome of the study was the average reduction in left ventricular mass indexed for body surface area from baseline to 1 year. A mixed model was used with left ventricular mass index (LVMI) as the outcome variable. Fixed effects were indicator variables for time, treatment and their interaction. Random effect was subject and statistical inference was made using the maximum likelihood estimator. No imputation was made for missing data. (NCT00582114)
Timeframe: Baseline, 6 months, 12 months
| Intervention | g/m^2 (Mean) | |
|---|---|---|
| LVMI Change from baseline, 6 months | LVMI Change from baseline, 12 months | |
| Atenolol | -8.4 | -21.5 |
| Lisinopril | -3.4 | -15.1 |
10 reviews available for atenolol and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
[Arterial stiffness, wave reflections and myocardial protection: the REASON project].
Topics: Antihypertensive Agents; Arteries; Atenolol; Blood Pressure; Diastole; Drug Combinations; Humans; Hy | 2003 |
Implications of the LIFE trial.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; At | 2003 |
[New perspectives of the use of angiotensin II receptor blocker].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diabetes Mellit | 2003 |
Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2004 |
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2007 |
Therapeutic options in minimizing left ventricular hypertrophy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2000 |
Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Atrial Fibrillation; Bradycardia; Calcium Channel Block | 2000 |
[Results from the LIFE study: promising effects of new hypertensive agents].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II; Antihypertensive Agents; Atenolol; Humans; Hyper | 2002 |
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Atenolol; Calcium Channe | 2002 |
142 trials available for atenolol and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Sex Differences in Atrial Fibrillation and Associated Complications in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study.
Topics: Atenolol; Atrial Fibrillation; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left | 2023 |
Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Humans; Hypertension; Hypertro | 2017 |
Impact of achieved systolic blood pressure on renal function in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Female; Glomerular Fil | 2016 |
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Comorbidity; Diabetes Mellitus, Type 2; D | 2013 |
Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment.
Topics: Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Electrocardiography; Female; Humans; H | 2014 |
Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2013 |
Long-term antihypertensive treatment fails to improve E/e' despite regression of left ventricular mass: an Anglo-Scandinavian cardiac outcomes trial substudy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Drug Therapy, Combi | 2014 |
Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Early Termination of Clinical T | 2014 |
Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cross-Sectional Studies; Female; Humans; | 2014 |
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; Cause of Death; De | 2014 |
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure | 2015 |
Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis.
Topics: Adult; Aged; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure Monitoring, Ambulatory; Early | 2015 |
Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Double-Blind Method; E | 2015 |
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascu | 2015 |
Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2015 |
Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Fem | 2017 |
Efficacy of exercise, losartan, enalapril, atenolol and rilmenidine in subjects with blood pressure hyperreactivity at treadmill stress test and left ventricular hypertrophy.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Enalapril; Exercise Test; Exercise Therapy | 2009 |
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocard | 2009 |
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diastole; Electrocardiography; Fem | 2009 |
The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SI
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Comorbidity; Echocardiography, D | 2009 |
Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study).
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Echocardiography; Female; Humans; Hypertens | 2009 |
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Death, Sudden, Card | 2009 |
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2008 |
Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Double-Blind M | 2010 |
[Echocardiography of left ventricular mass in patients with essential hypertension].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Double-Blind Met | 2009 |
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Fem | 2009 |
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hy | 2010 |
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Cardiovascular Diseases; Cause of Dea | 2010 |
Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Electrocardiography | 2011 |
Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2011 |
Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
Topics: Aged; Alcohol Drinking; Analysis of Variance; Antihypertensive Agents; Atenolol; Atrial Fibrillation | 2012 |
The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hyd | 2012 |
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Hemodynamics; Humans; Hypertension; | 2012 |
Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Heart Failure; Humans; Hypertens | 2012 |
Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Comorbidity; Double-Bl | 2012 |
Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study.
Topics: Adult; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure; Blood Pressure Determi | 2002 |
Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Echocardiography; Fema | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Prevention of cardiovascular morbidity with angiotension receptor blockade: life after LIFE.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Clinical Pr | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
Topics: Adult; Aged; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Atenolol; Biphenyl Compounds; B | 2002 |
Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Aged; Antihypertensive Agents; Atenolol; Female; Humans; Hypertension; Hypertrophy, Left Ventricular | 2002 |
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Doubl | 2003 |
B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2003 |
Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients.
Topics: Adult; Antihypertensive Agents; Aortic Diseases; Arteriosclerosis; Atenolol; Blood Pressure; C-React | 2003 |
[Arterial stiffness, wave reflections and myocardial protection: the REASON project].
Topics: Antihypertensive Agents; Arteries; Atenolol; Blood Pressure; Diastole; Drug Combinations; Humans; Hy | 2003 |
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Disease | 2003 |
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography; Electrocardiography; F | 2003 |
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Dia | 2003 |
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Dia | 2003 |
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Dia | 2003 |
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Dia | 2003 |
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihyperten | 2003 |
Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy.
Topics: Adipocytes; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Double-Blind Method; Female; Geno | 2003 |
Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atenolol; Biphenyl Co | 2003 |
Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Antihypertensive Agents; Atenolol; Bipheny | 2004 |
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Asian People; Atenolol; Black People; Blood Pressu | 2004 |
Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; European Union; Female; Humans; Hyperten | 2004 |
[Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. Results of LIFE study].
Topics: Anti-Arrhythmia Agents; Atenolol; Humans; Hypertrophy, Left Ventricular; Losartan; Remission Inducti | 2003 |
[Treatment of hypertension in patients with left ventricular hypertrophy].
Topics: Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hypertension; Hypertro | 2004 |
Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Follow-Up Studies; Heart Ventric | 2004 |
Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Topics: Antihypertensive Agents; Atenolol; Biphenyl Compounds; Double-Blind Method; Female; Genotype; Humans | 2004 |
Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Catecholamines; Female; Follow-Up Studie | 2004 |
Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography; Electrocardiography; F | 2004 |
Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Follow-Up Studies; | 2004 |
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Alcohol Drinking; Antihypertensive Agents; Atenolol; Female; Humans; Hypert | 2004 |
Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Topics: Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure; Endothelin-1; Female; Genotyp | 2004 |
A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Carotid Arteries; Female; Genotype; Glycoproteins; Hum | 2004 |
Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Alleles; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hyperten | 2004 |
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.
Topics: Aged; Anti-Infective Agents; Atenolol; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hyp | 2004 |
Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Carotid Arteries; D | 2004 |
Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers | 2004 |
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Diuretics; | 2004 |
Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Drug Therapy, Combi | 2004 |
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2004 |
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2004 |
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2004 |
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2005 |
Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Antihypertens | 2004 |
Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Diastole; Echocardiography; Fema | 2005 |
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Analysis of Variance; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Humans; | 2004 |
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Confounding Factors, Epi | 2005 |
Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy.
Topics: Aged; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Female; Humans; Hypertension; Hypertrophy | 2005 |
Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA).
Topics: Adult; Aged; Atenolol; Dihydropyridines; Echocardiography; Female; Humans; Hypertension; Hypertrophy | 2005 |
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
Topics: Aged; Atenolol; Body Mass Index; Body Weight; Cardiovascular Diseases; Female; Humans; Hypertension; | 2005 |
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atenolol; Drug | 2005 |
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Aortic Valve; Atenolol; Cardiovascular Diseases; Double- | 2005 |
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr | 2006 |
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Atenol | 2006 |
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Complications; Diabetes Mellitu | 2006 |
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Doubl | 2006 |
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albumins; Antihypertensive Agents; Atenolol; Biomarkers; C-Reactive Protein | 2006 |
Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Block | 2006 |
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Double-Blind Method; Electrocardiograp | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Blood Pressure | 2006 |
Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Biomarkers; Bl | 2006 |
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Echocardiograph | 2007 |
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2007 |
Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Biphenyl Co | 2007 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Death, Sudden, Cardiac; Double-Blind Met | 2007 |
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cost-Benefit Analy | 2007 |
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2007 |
Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardio | 2007 |
Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atenolol; Biomarkers; | 2007 |
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Compli | 2007 |
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Diabetes Mellitus | 2008 |
Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Fema | 2007 |
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blin | 2008 |
Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography, Doppler; Female; Human | 2008 |
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Female; | 2008 |
Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
Topics: Age Factors; Albuminuria; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Carotid Artery, | 2008 |
The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2008 |
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Electrocardiography | 2008 |
Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study.
Topics: Adult; Aged; Atenolol; Blood Pressure; Double-Blind Method; Enalapril; Female; France; Humans; Hydro | 1993 |
[The midterm inefficacy of 2 different dosages of chlorthalidone (50 and 25 mg/day) in the regression of left ventricular mass in arterial hypertension].
Topics: Aged; Atenolol; Blood Pressure; Chi-Square Distribution; Chlorthalidone; Enalapril; Follow-Up Studie | 1995 |
[Effect of 3 hypertensive++ agents on ventricular geometry and function].
Topics: Atenolol; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Midd | 1995 |
The effects of diuretic and beta-blocker treatment on cardiac and vascular structural changes in untreated essential hypertensive patients.
Topics: Adult; Atenolol; Blood Pressure; Chlorthalidone; Female; Humans; Hypertension; Hypertrophy, Left Ven | 1993 |
Beneficial effect of isradipine on the development of left ventricular hypertrophy in mild hypertension.
Topics: Aged; Atenolol; Blood Pressure; Double-Blind Method; Exercise Tolerance; Heart Rate; Heart Ventricle | 1993 |
Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhib | 1997 |
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II; Angiotensin-Converting Enzyme | 1997 |
Hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment. Influence on LVH, proteinuria and metabolic parameters. The HANE Trial Research Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Ant | 1997 |
Effect of treatment of isolated systolic hypertension on left ventricular mass.
Topics: Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Diuretics; Female; Follow-Up Studies; Heart | 1998 |
A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Antihypertensive Agents; Atenolol; Benzimi | 1998 |
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Echocardiogr | 1998 |
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Body Mass Index; Double- | 1998 |
Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Female; Huma | 1999 |
Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Double-Blind Method; Female; Huma | 1999 |
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diuretics; Drug | 1999 |
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hyp | 2000 |
Comparison of quinapril versus atenolol: effects on blood pressure and cardiac mass after renal transplantation.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2000 |
Effect of celiprolol on cardiac hypertrophy in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Celi | 2000 |
Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Electrocardiography; F | 2000 |
Regression of left ventricular hypertrophy in human hypertension with irbesartan.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Atenolol; Biphenyl Compo | 2001 |
Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Blood | 2001 |
Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihyper | 2002 |
Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Diastole; Echocardiography; Electrocardiogr | 2002 |
Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (
Topics: Aged; Alleles; Angiotensin Receptor Antagonists; Angiotensinogen; Antihypertensive Agents; Atenolol; | 2002 |
Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Blood Pressure; Cro | 2002 |
Left ventricular mass regression in elderly hypertensives.
Topics: Aging; Atenolol; Blood Pressure; Coronary Circulation; Delayed-Action Preparations; Echocardiography | 1992 |
52 other studies available for atenolol and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Atrial Function, Left; Electrocardiography; Fe | 2016 |
Provokable left ventricular outflow tract obstruction in a patient without hypertrophy.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Atenolol; Cardiac Pacing, Artificial; Diagnostic Imaging; D | 2009 |
Slower heart rates for healthy hearts: time to redefine tachycardia?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2008 |
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardio | 2010 |
Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Atenolol; Benzopyrans; Blood Pressure; Cardiovascular D | 2010 |
Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
Topics: Aged; Albuminuria; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol, | 2010 |
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Blood Pressure; | 2010 |
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Follow-Up S | 2011 |
Is hydrochlorothiazide more effective on LVH in nonresponders to losartan than in those to atenolol?
Topics: Antihypertensive Agents; Atenolol; Electrocardiography; Humans; Hydrochlorothiazide; Hypertrophy, Le | 2010 |
[Mitral valve dysplasia in a cat causing reversible left ventricular hypertrophy and dynamic outflow tract obstruction].
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Atenolol; Cat Diseases; Cats; Echocardiography; Hea | 2011 |
[Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Dose-R | 2002 |
No morbidity-mortality. Commentary.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Diabe | 2002 |
[Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cl | 2002 |
[German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenol | 2002 |
[What are the consequences of the LIFE Study for general practice].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenol | 2002 |
New strategies for prevention of ischemic stroke: the LIFE study.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol | 2003 |
[Left ventricular hypertrophy. Recent aspects of diagnosis and therapy].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2002 |
[Losartan in isolated systolic hypertension--convincing results of a LIFE sub-group study].
Topics: Aged; Antihypertensive Agents; Atenolol; Cause of Death; Double-Blind Method; Humans; Hypertension; | 2003 |
The LIFE study: the straw that should break the camel's back.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; My | 2003 |
Effect of beta-adrenoceptor antagonist and angiotensin-converting enzyme inhibitor on hypertension-associated changes in adenylyl cyclase type V messenger RNA expression in spontaneously hypertensive rats.
Topics: Adenylyl Cyclases; Adrenergic beta-Antagonists; Aging; Angiotensin-Converting Enzyme Inhibitors; Ani | 2003 |
Dynamic obstruction of the left ventricular outflow tract in four young dogs.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Atenolol; Diagnosis, Differential; Dog D | 2003 |
Summaries for patients. Benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihyperten | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
[LIFE study proves preventive action. With losartan to do even more against stroke].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Co | 2003 |
Effects of exercise and beta-blocker on blood pressure and baroreflexes in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Baroreflex; Bisoprolol; Blood Pressure; Body Weight; | 2003 |
LIFE: losartan versus atenolol.
Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Ther | 2003 |
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Electrocardiography; Female; Human | 2004 |
Genetic enhancement of ventricular contractility protects against pressure-overload-induced cardiac dysfunction.
Topics: Actins; Animals; Antihypertensive Agents; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Cardi | 2004 |
[Optimizing antihypertensive therapy. In 5 years 35,000 strokes are preventable].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2004 |
Long-term efficacy of doxazosin plus atenolol in the management of severe and sustained arterial hypertension and reversibility of the cardiac damage induced by chronic cathecolamine excess. A case report in a young girl with recurrent, functioning paraga
Topics: 3-Iodobenzylguanidine; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Atenolol; Blood Pr | 2004 |
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2005 |
Keeping tabs on your heart while treating BP.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan | 2005 |
Letter regarding article by Devereux et al, "regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial".
Topics: Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Humans; Hypertension; Hypertrophy, Left | 2005 |
Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Cost-Benefit Analysis; Double-Bli | 2005 |
Enlarged hearts, larger threats. But reducing heart-muscle mass can blunt cardiac dangers.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertrophy, Left Ventricular; Losartan | 2005 |
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Cholesterol; Cr | 2006 |
A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Cohort Studies | 2006 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Aorta; Atenolol; Baroreflex; Biphenyl Compounds; Blood Pressure; C | 2006 |
Treatment of diastolic dysfunction in hypertensive left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2006 |
Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension.
Topics: Antihypertensive Agents; Atenolol; Enalapril; Female; Genotype; Heterozygote; Humans; Hypertension; | 2006 |
In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE)
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Comorbidity; Diabetes Me | 2007 |
Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atenolol; Blood Pressure; Blood Pr | 2007 |
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Heart Ventricles; Humans; Hypert | 2008 |
Effect of prolonged beta-adrenergic blockade induced by atenolol on left ventricular remodeling after acute myocardial infarction in the rat.
Topics: Animals; Atenolol; Heart Rate; Hypertrophy, Left Ventricular; Male; Myocardial Infarction; Myocardiu | 1995 |
Enhanced expression of heparin-binding EGF-like growth factor and its receptor in hypertrophied left ventricle of spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodies; Atenolol | 1998 |
Comparative effects of atenolol-based and amlodipine-based antihypertensive therapy on QT dispersion in hypertensive subjects.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Electrocardiography; Humans; Hypertension; Hypertroph | 2001 |
Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressu | 2002 |
Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).
Topics: Aged; Aged, 80 and over; Albumins; Antihypertensive Agents; Atenolol; Blood Pressure; Creatinine; El | 2002 |
[Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pr | 2002 |
ARB superior to beta blocker in preventing adverse outcomes in older, high-risk hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Humans; Hyp | 2002 |
Obstructive left ventricular hypertrophy. Reversibility of outflow tract obstruction by drug therapy.
Topics: Aged; Aged, 80 and over; Atenolol; Echocardiography, Doppler; Female; Humans; Hypertrophy, Left Vent | 1992 |